MedCity News June 6, 2024
Three upcoming Supreme Court decisions have the potential to radically change FDA regulation of medications.
The cases, which involve “Chevron deference” and the abortion pill mifepristone, were discussed on a panel during the BIO conference in San Diego.
In coming weeks, the U.S. Supreme Court will decide whether two fishing companies must pay the costs of third-party observers to monitor a vessel’s compliance with regulations. On its face, the legal interpretation of a 1970s-era law seems completely unrelated to biotechnology and medicine in 2024. But the outcome of the cases could change how the FDA interacts with the industry it regulates.
The precedent is rooted in another case that also has nothing to do directly with the biopharma industry. Chevron...
Today's Sponsors
Today's Sponsor